Skip to Content

Significant effect of PARP-inhibitor olaparib plus abiraterone in patients with mCRPC

Patients with metastatic castration-resistant prostate cancer (mCRPC) unfortunately live less than 2 years in real world settings. PROPEL is a phase III study randomizing around 800 patients with mCRPC to investigate the efficacy of the combination of the PARP-inhibitor olaparib and abiraterone as first-line therapy on progression free survival rates. In this MEDtalk, Professor Fred Saad presents the outstanding results from PROPEL, suggesting significant efficacy on this drug combination regardless of HRR mutation status.

Fred Saad

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top